Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 23 (2), 2024
Pp 8053 - 8070

Gestational Diabetes: Management, Pharmacist Control, and Nursing Intervention Plans

[1]-Abdurahman Ali Ahmad Mehdaly,[2]-Albaraa Musa Hussain Mahzari,-[3]Sultan Mohammed Abdullah Baytali,[4]-Ahmed Ali Fassal Alhadri,[5]-Yasir Mohammed Mousa Alajam,[6]-Alhanouf Mohammed Mudibi Alwi,[7]-Huda Ali Ibrahim Jaafari,[8]-Ziyad Hassan Mousa Abu Dabbaj,[9]-Gassem Yahya Hassan Almoharg,[10]-Abdullah Yahya Ahmed Ghurab

1. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster
2. Ksa, Ministry Of Health, Chest Disease Hospital-Jazan Health Cluster
3. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster
4. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster
5. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster
6. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster
7. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster
8. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster
9. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster
10. Ksa, Ministry Of Health, Baish General Hospital - Jazan Health Cluster

Abstract:

Background: Gestational Diabetes Mellitus (GDM) is a condition characterized by glucose intolerance detected during pregnancy, posing significant risks to both maternal and fetal health. GDM increases the likelihood of adverse obstetric outcomes such as macrosomia, shoulder dystocia, and preterm birth, and it also heightens the need for Caesarean sections. Furthermore, women diagnosed with GDM are at an elevated risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular diseases (CVD) later in life. Recent studies suggest that GDM's impact extends beyond pregnancy, potentially affecting long-term maternal health and the health of offspring.

Aim: This article aims to explore the management of GDM, focusing on the role of pharmacists and nursing interventions in controlling and mitigating the condition's immediate and long-term effects on maternal and child health.

Methods: The review synthesizes data from various studies and clinical observations regarding the pathophysiology, management, and long-term outcomes associated with GDM. The article delves into maternal health post-GDM pregnancy, including the increased risk of T2DM, cardiovascular diseases, and complications in offspring. It also discusses the role of early interventions, risk factors, and preventative measures.

Results: The review highlights the critical connection between GDM and the development of T2DM and CVD, emphasizing the progression of β-cell dysfunction that underpins both conditions. Additionally, the

study reports that women with a history of GDM exhibit higher rates of obesity, hypertension, and metabolic syndrome postpartum, contributing to the elevated risk of future health complications. Offspring of mothers with GDM are also at risk of long-term cardiometabolic issues.

Conclusion: The management of GDM is essential not only for pregnancy outcomes but also for long-term maternal and child health. Early intervention, including the role of pharmacists and nursing staff in monitoring glycemic control and cardiovascular risk, is critical in reducing the risks of T2DM and CVD. Furthermore, recognizing the early signs of metabolic dysfunction in women before and during pregnancy can aid in preventing the onset of GDM and its associated complications.

Keywords: Gestational diabetes, Type 2 diabetes, cardiovascular disease, β-cell dysfunction, maternal health, nursing interventions, pharmacist control, metabolic syndrome.

Received: 16 October 2024 **Revised:** 29 November 2024 **Accepted:** 13 December 2024

Introduction:

Gestational diabetes mellitus (GDM) is characterized by glucose intolerance of varying degrees, which emerges or is first detected during pregnancy. It is regarded as a medical complication of pregnancy that significantly increases the risk of adverse obstetric outcomes, such as macrosomia, shoulder dystocia, birth injuries, prematurity, perinatal mortality, and the necessity for Caesarean delivery [1]. Consequently, screening for GDM and its subsequent antenatal management have become integral components of routine obstetric care. However, the ramifications of GDM extend beyond pregnancy itself [2]. Notably, GDM has long been recognized as a predictor of future susceptibility to type 2 diabetes mellitus (T2DM) in affected women. More recently, there has been increasing acknowledgment that GDM is also associated with an elevated risk of other chronic conditions, particularly cardiovascular disease (CVD) [2]. Furthermore, the risk factors contributing to these conditions may be detectable even prior to the pregnancy in which GDM is diagnosed. In fact, the early origins of these risk factors can be observed in the offspring of women with GDM. As discussed in this review, the emerging understanding from this body of research is that, although GDM is diagnosed and managed during pregnancy, its consequences have lifelong implications for both the mother and her child.

Maternal Health After GDM Pregnancy:

Type 2 Diabetes Mellitus:

Since its initial identification, gestational diabetes mellitus (GDM) has been closely associated with the development of type 2 diabetes mellitus (T2DM). Notably, in 1964, O'Sullivan and Mahan [3] demonstrated that specific glycemic thresholds during the 3-hour 100 g oral glucose tolerance test (OGTT) in pregnancy could predict the risk of T2DM in women later in life, establishing the first diagnostic criteria for GDM. Over subsequent decades, numerous studies have reinforced the notion that maternal glycemia during pregnancy is a reliable predictor of future T2DM [2,4]. This relationship holds true regardless of the diagnostic criteria employed to identify GDM. Given that varying diagnostic criteria and thresholds label different levels of gestational

glycemia as GDM, it is evident that the risk of T2DM extends beyond the GDM category, encompassing individuals with lower levels of gestational glycemia as defined by less stringent criteria. For example, women with abnormal OGTT results, but who do not meet the criteria for GDM according to the National Diabetes Database, exhibit a higher risk of T2DM, though lower than that of those diagnosed with GDM [5-7]. It is now well-established that any form of dysglycemia during pregnancy corresponds to an increased risk of progressing to T2DM in the future, with GDM representing the most severe form of gestational dysglycemia and the highest subsequent T2DM risk [6-8]. The pathophysiological foundation for this association lies in pancreatic β-cell dysfunction.

The connection between GDM and T2DM is grounded in pancreatic β-cell dysfunction. Specifically, the insulin resistance that characterizes normal human pregnancy, beginning in mid-gestation, imposes a physiological challenge for β-cells, which must increase insulin secretion to maintain normoglycemia. Any failure of β-cells to adequately compensate for this increased demand results in dysglycemia during pregnancy, with GDM being the most extreme manifestation of this dysfunction. Notably, women who develop GDM exhibit a chronic β-cell defect, which initially becomes clinically evident through hyperglycemia during pregnancy due to insufficient compensatory response [9]. This β-cell dysfunction not only underpins the presentation of GDM but also plays a key role in the development of T2DM in the years following pregnancy [10]. Research has shown that β-cell function deteriorates in women with a history of GDM even within the first year postpartum, despite normal glucose tolerance at that time [7,11]. Over time, this progressive β-cell dysfunction leads to the development of pre-diabetes and eventually T2DM [7,12,13]. Therefore, the epidemiological and clinical link between GDM and T2DM is rooted in a shared pathophysiology of β-cell dysfunction. Studies assessing the risk of T2DM in women with a history of GDM have reported considerable variability, which can be attributed to several methodological factors. These include differences in GDM screening protocols and diagnostic criteria (which influence the severity of β-cell dysfunction and, consequently, the risk of T2DM), variations in postpartum surveillance protocols and adherence, and discrepancies in the non-GDM control population used for comparison. Despite these limitations, the overall literature suggests that women with a history of GDM face a 7- to 10-fold higher risk of developing T2DM compared to their peers [14,15], highlighting the substantial increase in the risk of a major chronic disease in young women of reproductive age.

Advanced Complications Associated with T2DM:

The relative youth of this high-risk population suggests that T2DM may develop at a relatively early age, leading to prolonged exposure to the metabolic dysfunction of diabetes over a lifetime. Since cumulative glycemic exposure is a known determinant of vascular complications in T2DM, it is reasonable to expect that women with a history of GDM may experience a higher incidence of these complications [16,17]. Consistent with this hypothesis, women with prior GDM exhibit an increased risk of advanced retinopathy, which is further influenced by the onset of T2DM [18]. Additionally, these women have a higher incidence of advanced nephropathy

(including the need for dialysis) and hospitalizations for foot infections (e.g., foot ulcers, cellulitis, or osteomyelitis), conditions indicative of neuropathy or peripheral vascular disease, with both risks being contingent upon the development of T2DM [18]. While women with a history of GDM do not appear to face these advanced complications in the absence of T2DM, studies have reported elevated estimated glomerular filtration rates, possibly signaling early glomerular hyperfiltration and renal dysfunction in this group [19]. Increased microalbuminuria has also been observed in women with prior GDM as they progress to pre-diabetes [20], suggesting a concurrent progression of renal impairment and worsening glucose tolerance early in the disease process.

A similar progression is observed in the relationship between GDM and liver disease. Specifically, the presence of liver fat detected on abdominal ultrasound early in pregnancy has been shown to predict subsequent dysglycemia during the second trimester [21]. In the years following delivery, women with a history of GDM exhibit higher rates of fatty liver, with the severity of liver fat accumulation correlating with glucose intolerance [22-25]. Ultimately, women with previous GDM face an increased long-term risk of advanced liver disease, including cirrhosis, liver failure, or the need for transplantation, a risk that materializes primarily in those who develop T2DM over the intervening years [26]. Collectively, the risk of advanced ophthalmologic, nephropathic, and hepatic complications in women with a history of GDM appears to be contingent upon the subsequent development of T2DM, with both renal and liver dysfunction demonstrating long-term progression.

CVD with or without T2DM

A similar long-term association exists between gestational diabetes mellitus (GDM) and cardiovascular disease (CVD), with one critical distinction: the increased risk of CVD outcomes in women with a history of GDM cannot be solely attributed to the development of type 2 diabetes mellitus (T2DM) [18,27]. Over the last decade, numerous studies have consistently shown that women who have experienced GDM are at a heightened risk of CVD events, including both fatal and non-fatal ischemic heart disease and cerebrovascular events, compared to women without a history of GDM [18,27-34]. A meta-analysis involving over 5 million women and more than 100,000 events has revealed that women with GDM have a two-fold increased risk of future CVD events (relative risk [RR], 1.98; 95% confidence interval [CI], 1.57 to 2.50) when compared to their counterparts without GDM [27]. Notably, meta-regression analysis indicated that the rates of incident T2DM across studies did not significantly impact this risk. Furthermore, even among women who did not develop T2DM, a history of GDM still predicted a 56% increased risk of future CVD events (RR, 1.56; 95% CI, 1.04 to 2.32) [27]. In addition to major cardiovascular events, GDM has also been linked to an increased incidence of heart failure [34]. The recognition that the increased incidence of CVD in women with a history of GDM is not entirely dependent on the subsequent development of T2DM raises questions about the underlying determinants of cardiovascular risk in this population. In this regard, it is noteworthy that studies have consistently found that women with a history of GDM exhibit a higher prevalence of cardiometabolic risk factors, such as dyslipidemia, hypertension, overweight/obesity, and metabolic syndrome,

compared to their peers [35-39]. This unfavorable cardiovascular risk profile is often apparent as early as three months postpartum [37,38]. The presence of these risk factors so soon after delivery raises the question of whether they are a consequence of the GDM pregnancy or whether they may precede the diagnosis of GDM. To explore this, it is important to consider the health status of women prior to their GDM pregnancy.

Maternal Health Prior to GDM Pregnancy

There is substantial evidence suggesting that women who later develop GDM exhibit early metabolic changes even before the diagnosis. For instance, alterations in glucose, insulin, and insulin-like growth factor-binding protein-1 levels have been detected in the amniotic fluid of women in the first trimester, long before GDM is diagnosed [40]. Additionally, fetal overgrowth may occur prior to the diagnosis of GDM [41]. First-trimester measurements of circulating biomarkers and analytes, such as glycemic levels, fasting insulin, adiponectin, HDL cholesterol, triglycerides, C-reactive protein, tissue plasminogen activator antigen, and insulin-like growth factor-binding protein-2, can predict a higher likelihood of developing GDM later in pregnancy [42]. These findings suggest that a detectable phenotype may exist in early pregnancy that predicts an increased risk of developing GDM, raising the question of whether such metabolic changes could be evident even before conception. Prior to pregnancy, women who later develop GDM exhibit distinct differences compared to those who do not, including higher levels of A1c, fasting glucose, LDL cholesterol, and triglycerides, alongside lower levels of HDL cholesterol [43-46]. Furthermore, over the five years preceding their index pregnancy, these cardiovascular risk factors follow divergent trajectories, with women who later develop GDM exhibiting a worsening of these risk factors compared to their peers, leading to an exacerbation of differences over time [46]. These divergent trajectories may be further influenced by the pregnancy, resulting in a greater disparity in the postpartum period [47]. Pregnancy thus acts as a critical juncture, revealing a population of young women who are gradually developing a high-risk cardiometabolic profile. Moreover, the progressive worsening of their cardiometabolic risk factors in the years leading up to pregnancy suggests that this pathological process may begin earlier in life than previously understood.

Health of the Offspring of GDM Pregnancy

The evidence indicating an adverse cardiometabolic profile prior to pregnancy suggests that the increased risk of pre-gestational T2DM, GDM, and post-gestational T2DM may have origins in early life. Following the seminal work by Barker [49] on the developmental origins of health and disease, significant interest has developed in understanding the intergenerational transmission of cardiometabolic risk. The impact of maternal diabetes on offspring is two-fold: it results in both immediate perinatal complications and long-term risks for cardiometabolic diseases. Although the focus of this review is maternal GDM, it is important to note that many original studies investigating the outcomes of maternal hyperglycemia have combined populations exposed to maternal hyperglycemia, including pre-gestational diabetes and GDM.

Postnatal Complications of In Utero Exposure to Gestational Diabetes

Maternal obesity, excessive weight gain during pregnancy, and hyperglycemia are well-established risk factors for fetal overnutrition, leading to hyperinsulinism, increased production of insulin-like growth factor-1, and consequent fetal overgrowth. Fetal hyperinsulinism is closely linked to an excessive increase in fat mass, disrupted fetal lung surfactant production [50], resulting in neonatal respiratory distress syndrome, and neonatal hypoglycemia [51]. Additionally, maternal hyperglycemia is associated with relative fetal hypoxia, and in severe cases, can lead to fetal asphyxia and stillbirth [52]. Maternal GDM has also been associated with congenital anomalies affecting the heart, genitourinary tract, facial features (such as cleft lip and palate), and the central nervous system. A recent large-scale epidemiological study [53] found that GDM exposure significantly increases the overall risk of congenital anomalies (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.24 to 1.31), even when adjusting for maternal age, ethnicity, education, smoking habits, parity, pre-pregnancy body mass index (BMI), hypertension, and infant sex. The perinatal and postnatal morbidity observed in offspring exposed to maternal hyperglycemia spans the spectrum of dysglycemia and serves as a precursor to long-term complications.

Childhood Cardiometabolic Complications

The effects of fetal overnutrition and overgrowth extend beyond infancy into childhood, resulting in increased neonatal and infant fat mass, and heightened risks of being overweight and obesity later in childhood. Pedersen's early hypothesis [54] linking intrauterine hyperglycemia with increased obesity and type 2 diabetes (T2DM) risk in offspring has gained substantial empirical support from recent epidemiological and longitudinal birth cohort studies. These studies consistently show that offspring exposed to maternal hyperglycemia and GDM have greater birth weights, higher neonatal fat mass [55,56], abdominal adiposity [57], and increased rates of overweight and obesity [58-63]. A pivotal study of sibling pairs from the Akimal O'odam (Pima) population comparing offspring born before and after a maternal diabetes diagnosis revealed an elevated risk of childhood obesity due to maternal diabetes exposure, independent of genetic and environmental factors [64]. Although studies on the relationship between GDM exposure and body mass index (BMI) have yielded mixed results, more recent analyses from the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS) and Exploring Perinatal Outcomes in Children (EPOCH) study support a significant link between maternal diabetes exposure and elevated offspring adiposity. The HAPO FUS indicated that exposure to GDM during pregnancy was associated with a 54% higher odds of childhood obesity, a 35% increase in body fat, and a 34% higher waist circumference in children aged 10 to 14 years [65]. Similarly, the EPOCH study, conducted in a multiethnic cohort of youth from Colorado, found that GDM exposure was positively correlated with offspring BMI, waist circumference, and both visceral and subcutaneous adiposity, with the relationship persisting from childhood (mean age 10.5 years) into adolescence (mean age 16.7 years) and showing limited impact from postnatal environment [66]. These studies demonstrated attenuated, but enduring effects, even when accounting for maternal pre-pregnancy BMI. Although several studies that adjusted maternal weight (pre-pregnancy BMI and/or

gestational weight gain) still found significant links between maternal diabetes exposure and childhood obesity, the degree of childhood adiposity varied across studies, indicating that risk is influenced by factors such as the population studied, the timing and extent of maternal dysglycemia exposure, and treatment protocols. Notably, not all offspring exposed to diabetes in utero exhibit large-for-gestational-age status, excess adiposity, or later development of T2DM, pointing to the necessity for further research on the mechanisms of intergenerational risk inheritance and the interaction of these mechanisms with postnatal environmental factors.

Childhood Risk of Developing Insulin Resistance and Dysglycemia

Beyond the direct impact of obesity, elevated maternal glycemia during pregnancy also predicts metabolic disorders such as insulin resistance, impaired glucose tolerance, and T2DM in offspring. Early studies in the Akimal O'odam population provided initial evidence linking maternal hyperglycemia to increased risks of childhood obesity, insulin resistance, and T2DM in offspring [71]. More recent findings from the HAPO FUS [69] showed that offspring born to mothers with GDM exhibited higher plasma glucose levels during a 75 g oral glucose tolerance test (OGTT) at 30, 60, and 120 minutes, even after adjusting for maternal and child obesity. Exposure to maternal GDM was also associated with decreased insulin sensitivity, impaired β-cell compensation, and nearly double the odds of developing impaired glucose tolerance (OR, 1.96; 95% CI, 1.41 to 2.73) between ages 10 to 14 years. The SEARCH for Diabetes in Youth (SEARCH) study confirmed these findings, indicating that maternal diabetes and obesity during pregnancy accounted for 47% of the risk for childhood T2DM in offspring [72]. A large Canadian cohort study reinforced the importance of GDM and T2DM exposure as independent risk factors for early-onset T2DM, with both being linked to a faster progression to diagnosis in offspring [70]. Thus, maternal diabetes exposure—both GDM and T2DM—is a critical factor in the development of pre-diabetes and T2DM in offspring, independent of obesity and excess adiposity, highlighting the potential role of altered β-cell development and function.

Although the precise pathophysiological mechanisms linking maternal diabetes exposure to offspring obesity and metabolic dysregulation remain unclear, increasing evidence suggests that epigenetic modifications, such as DNA methylation changes, may mediate the link between prenatal exposure and later disease development [73-75]. Studies have shown that maternal diabetes exposure leads to altered DNA methylation patterns in genes related to insulin signaling and metabolic pathways, which may persist into adolescence and contribute to glucose and lipid metabolism dysregulation [75-77]. Analysis of cord blood in offspring exposed to maternal diabetes revealed distinct methylation patterns in genes controlling metabolic and insulin-related pathways [75,76,78]. These epigenetic alterations, which can persist in adolescence, may provide an important mechanism linking early life exposures to later metabolic disorders.

Long-term Health Consequences in Offspring Exposed to Gestational Diabetes

The independent effect of gestational diabetes mellitus (GDM) exposure on the long-term cardiovascular risk in offspring remains challenging to isolate due to the frequent coexistence of

obesity, central adiposity, and dysglycemia in affected individuals. In fact, the elevated cardiovascular risk in these offspring is likely multifactorial, with obesity, insulin resistance, hyperinsulinism, and type 2 diabetes mellitus (T2DM) all contributing significantly. However, efforts have been made to identify whether specific cardiovascular risk factors, such as hypertension and dyslipidemia, can be linked directly to maternal diabetes exposure in utero. Early studies within the Akimal O'odam population indicated an increase in systolic blood pressure by 11 mm Hg in offspring exposed to maternal diabetes, independent of sex, current adiposity measures, and family history of diabetes [79]. A subsequent large cohort study in Portugal reported higher systolic and diastolic blood pressure in 10-year-old children born to mothers with GDM compared to unexposed peers, with this association being mediated by childhood BMI and varying by sex, with boys exhibiting a higher risk than girls [80].

Hypertension risk in offspring exposed to maternal diabetes may partly arise from early renal dysfunction. Evidence suggests that up to 50% of youth with T2DM develop micro- and macrovascular complications, including end-stage renal disease requiring dialysis within 15 years of diagnosis [81,82]. In a cohort of predominantly First Nations adolescents with T2DM, approximately 30% had albuminuria 2 years post-diagnosis, indicating that kidney disease develops early and may be independent of sustained hyperglycemia [83]. Additionally, a national surveillance study revealed that 5.4% of Canadian youth with T2DM exhibited albuminuria in the first year of diagnosis, with those exposed to T2DM in utero more likely to be affected than unexposed youth [84]. Mechanistically, nephrogenesis is not completed until 36 weeks of gestation, and intrauterine exposure to T2DM may significantly influence nephron endowment and subsequent kidney function [85]. Animal models have shown that maternal diabetes exposure in utero can impair renal development, reducing nephron endowment at birth and contributing to glomerular hypertrophy, hyperfiltration, and albuminuria [86,87]. Studies examining broader cardiometabolic risk factors include follow-up data from the EPOCH cohort [88,89] and a Danish cohort study [90]. Short-term follow-up of children in the EPOCH cohort indicated that maternal GDM exposure was linked to increased waist circumference and elevated biomarkers of endothelial dysfunction, while long-term follow-up into adolescence revealed associations with unfavorable lipid profiles in girls (elevated total cholesterol and LDL cholesterol) and increased systolic blood pressure in boys. Notably, the relationship with lipid profiles in girls was no longer significant after adjusting for maternal GDM treatment, suggesting that maternal hyperglycemia plays a crucial role in fetal dyslipidemic pathways. The Danish cohort study demonstrated that, after adjusting for childhood BMI, in utero GDM exposure was associated with insulin resistance, elevated fasting blood sugar, insulin and C-peptide levels, and central adiposity in offspring [90].

Few studies have assessed the impact of maternal GDM exposure on actual cardiovascular events in offspring. Two major population-based cohort studies have suggested an increased likelihood of cardiovascular disease (CVD) in offspring at ages 35 to 40 years. A Canadian cohort study reported that offspring exposed to GDM in utero had a 1.9-fold increased hazard for cardiovascular risk factors such as hypertension, dyslipidemia, and T2DM, and a 1.42-fold

increased risk of CVD (including myocardial infarction, heart failure, and cerebrovascular infarction) within 35 years, compared to unexposed offspring. The increased CVD morbidity was predominantly attributed to early-onset hypertension, T2DM, and dyslipidemia [91]. Similarly, a Danish study reported that exposure to GDM in utero was associated with higher rates of CVD (including heart failure, hypertension, deep vein thrombosis, and pulmonary embolism) in offspring by age 40, even after adjusting for maternal and paternal CVD history [33,92]. Notably, the highest associations were observed among offspring of mothers with a history of diabetes-related complications or CVD, highlighting the central role of chronic maternal hyperglycemia in determining offspring risk.

The causal link between intrauterine exposure and increased CVD risk is complex, compounded by maternal diabetes and obesity, and postnatal factors such as childhood obesity. Recent reviews of animal studies have demonstrated that maternal GDM or hyperglycemia can lead to offspring cardiovascular complications, including hypertrophy, left ventricular wall thickening, and systolic and diastolic dysfunction, partly driven by mitochondrial dysfunction in the heart [93]. In conclusion, current evidence strongly suggests the existence of an intergenerational cycle of cardiometabolic dysfunction, originating in utero and influencing health outcomes across the lifespan. Offspring exposed to maternal diabetes are at increased risk for metabolic disorders and GDM in pregnancy, which may perpetuate poor cardiometabolic health in subsequent generations. This underscores the need for a lifecycle approach to prevention, where interventions at various life stages are essential to mitigate these risks [94].

Nursing Intervention Plans:

Gestational Diabetes Mellitus (GDM) is a common pregnancy complication that results in elevated blood glucose levels and can lead to significant maternal and fetal health risks if not properly managed. The role of nursing interventions in managing GDM is crucial for ensuring that both maternal and fetal health are maintained throughout the pregnancy. The nursing intervention plan for GDM is designed to focus on continuous monitoring, patient education, and timely interventions aimed at preventing complications such as preeclampsia, fetal macrosomia, and type 2 diabetes later in life. This plan involves a comprehensive approach that includes assessment, goal setting, intervention, and evaluation. The first step in the nursing intervention plan involves a thorough assessment of the patient’s condition. The nurse must gather a complete medical history, identifying any risk factors for GDM, such as obesity, family history of diabetes, or previous GDM. Blood glucose levels must be regularly monitored, with attention to both fasting and postprandial levels, as these readings provide vital information regarding glucose control. Additionally, assessing the patient's dietary habits and physical activity levels is essential in understanding the potential areas for improvement. The nurse should also evaluate any signs of complications related to high blood sugar, such as excessive thirst, frequent urination, and fatigue. This comprehensive assessment allows the nurse to identify potential risks and initiate targeted interventions.

Following the assessment, the nurse formulates a care plan based on the identified needs and risks. Common nursing diagnoses for GDM include “Ineffective Health Management” related to the lack of knowledge about managing GDM, “Risk for Unstable Blood Glucose” due to inadequate dietary control or lack of physical activity, and “Risk for Injury” related to hyperglycemia and potential complications like preterm labor. Based on these diagnoses, the nurse sets SMART goals, such as maintaining blood glucose levels within the target range (e.g., fasting glucose 70-95 mg/dL and postprandial glucose < 120 mg/dL) and ensuring the patient demonstrates an understanding of the necessary dietary modifications by the next visit. The nurse may also set goals related to improving physical activity levels and preventing complications associated with uncontrolled blood glucose. The nursing interventions for GDM include several key strategies. First, blood glucose monitoring is a primary intervention. The nurse should teach the patient how to effectively monitor their glucose levels at home using a glucometer, and the nurse should reinforce the importance of regularly testing blood glucose levels as prescribed. Additionally, the nurse educates the patient on interpreting their readings, identifying patterns, and understanding when to seek help. Dietary counseling is also essential, as a well-balanced diet plays a crucial role in controlling blood sugar. The nurse works with a dietitian to help the patient develop a personalized meal plan, focusing on carbohydrate counting, portion control, and the timing of meals. Regular physical activity is another vital component of the intervention plan. The nurse should encourage exercise as it helps improve insulin sensitivity and maintain blood glucose levels. Finally, the nurse ensures that any prescribed medications, such as insulin, are administered correctly and educates the patient on proper insulin use, including adjustments based on glucose readings.

The nurse’s role also includes continuous monitoring for complications. Regular prenatal check-ups and monitoring of fetal well-being through ultrasounds and non-stress tests are essential to ensure that the fetus is not experiencing distress or abnormal growth patterns. The nurse should also assess for signs of preeclampsia, such as high blood pressure, proteinuria, and swelling. Emotional support is another key aspect of nursing care for GDM patients. Women with GDM may experience anxiety related to their condition, and the nurse provides reassurance and emotional support, ensuring the patient feels empowered to manage their condition. Providing education about the risks of GDM and the importance of self-management is critical for reducing anxiety and promoting adherence to the treatment plan. Evaluation is a critical part of the nursing intervention plan, as it allows the nurse to assess the effectiveness of the implemented strategies. The nurse should evaluate whether the patient’s blood glucose levels are within the target range and whether the patient has adhered to dietary and physical activity recommendations. The nurse also assesses fetal health and any signs of complications, adjusting the care plan as necessary. Regular follow-up appointments are essential to ensure that the patient continues to manage GDM effectively and that any emerging complications are identified early. In some cases, further interventions may be required if blood glucose levels are not well-controlled or if complications arise. In conclusion, the nursing intervention plan for gestational diabetes is a comprehensive approach that includes assessment, education, regular monitoring, and emotional support. Through

consistent intervention, the nurse plays a pivotal role in helping women with GDM achieve optimal health outcomes, reducing the risk of maternal and fetal complications, and improving long-term health for both mother and child. Effective management of GDM through nursing interventions is crucial for preventing the progression of type 2 diabetes and other associated cardiovascular complications later in life.

Conclusion:

Gestational Diabetes Mellitus (GDM) is a significant risk factor for future metabolic and cardiovascular diseases, both for the mother and her offspring. The pathophysiological mechanisms underlying GDM, such as β-cell dysfunction and insulin resistance, contribute to the increased risk of Type 2 Diabetes Mellitus (T2DM) in affected women. The longitudinal evidence shows that women diagnosed with GDM face a 7- to 10-fold increased risk of developing T2DM, and this risk is exacerbated by the progression of β-cell dysfunction, which begins during pregnancy and continues postpartum. Even in the absence of T2DM, women with a history of GDM remain at higher risk for cardiovascular diseases (CVD), with studies indicating a significant increase in the incidence of ischemic heart disease, cerebrovascular events, and heart failure. Pharmacists and nursing interventions are pivotal in the management of GDM, particularly in monitoring blood glucose levels and addressing cardiovascular risk factors such as hypertension, dyslipidemia, and obesity. Both professionals play an essential role in educating patients, recommending lifestyle modifications, and providing ongoing care post-pregnancy to manage and reduce the risk of T2DM and CVD. Nurses, for instance, can provide support by counseling women on dietary changes and physical activity, while pharmacists can optimize medication regimens for those who need pharmacological interventions. The long-term effects of GDM on maternal health underscore the importance of early screening and continuous monitoring. Furthermore, the offspring of mothers with GDM are also at heightened risk for metabolic disorders and congenital anomalies, which necessitates early pediatric follow-up to mitigate these risks. Given the increasing prevalence of GDM worldwide, it is crucial that healthcare systems integrate proactive strategies for both maternal and fetal care, aiming to prevent the future onset of chronic conditions associated with GDM. The recognition of GDM as a long-term health concern demands comprehensive management approaches that include preventive measures, early detection, and coordinated care across disciplines.

References:

1. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nat Rev Dis Primers. 2019; 5:47.

2. Fu J, Retnakaran R. The life course perspective of gestational diabetes: an opportunity for the prevention of diabetes and heart disease in women. EClinicalMedicine. 2022; 45:101294.

3. O'Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes. 1964; 13:278–85.

4. Saravanan P; Diabetes in Pregnancy Working Group; Maternal Medicine Clinical Study Group; Royal College of Obstetricians and Gynaecologists, UK. Gestational diabetes: opportunities for improving maternal and child health. Lancet Diabetes Endocrinol. 2020; 8:793–800.

5. Retnakaran R, Qi Y, Sermer M, Connelly PW, Zinman B, Hanley AJ. Isolated hyperglycemia at 1 hour on oral glucose tolerance test in pregnancy resembles gestational diabetes mellitus in predicting postpartum metabolic dysfunction. Diabetes Care. 2008; 31:1275–81.

6. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. Risk of early progression to prediabetes or diabetes in women with recent gestational dysglycaemia but normal glucose tolerance at 3-month postpartum. Clin Endocrinol (Oxf). 2010; 73:476–83.

7. Kramer CK, Swaminathan B, Hanley AJ, Connelly PW, Sermer M, Zinman B, et al. Each degree of glucose intolerance in pregnancy predicts distinct trajectories of β-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. Diabetes Care. 2014; 37:3262–9.

8. Retnakaran R, Shah BR. Abnormal screening glucose challenge test in pregnancy and future risk of diabetes in young women. Diabet Med. 2009; 26:474–7.

9. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005; 115:485–91.

10. Buchanan TA. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab. 2001; 86:989–93.

11. Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B. Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care. 2010; 33:1798–804.

12. Xiang AH, Kjos SL, Takayanagi M, Trigo E, Buchanan TA. Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus. Diabetes. 2010; 59:2625–30.

13. Xiang AH, Kawakubo M, Trigo E, Kjos SL, Buchanan TA. Declining beta-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care. 2010; 33:396–401.

14. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009; 373:1773–9.

15. Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and metaanalysis. BMJ. 2020; 369:m1361.

16. Beharier O, Sergienko R, Kessous R, Szaingurten-Solodkin I, Walfisch A, Shusterman E, et al. Gestational diabetes mellitus is a significant risk factor for long-term ophthalmic morbidity. Arch Gynecol Obstet. 2017; 295:1477–82.

17. Beharier O, Shoham-Vardi I, Pariente G, Sergienko R, Kessous R, Baumfeld Y, et al. Gestational diabetes mellitus is a significant risk factor for long-term maternal renal disease. J Clin Endocrinol Metab. 2015; 100:1412–6.

18. Retnakaran R, Shah BR. Role of type 2 diabetes in determining retinal, renal, and cardiovascular outcomes in women with previous gestational diabetes mellitus. Diabetes Care. 2017; 40:101–8.

19. Rawal S, Olsen SF, Grunnet LG, Ma RC, Hinkle SN, Granstrom C, et al. Gestational diabetes mellitus and renal function: a prospective study with 9- to 16-year follow-up after pregnancy. Diabetes Care. 2018; 41:1378–84.

20. Kew S, Swaminathan B, Hanley AJ, Connelly PW, Sermer M, Zinman B, et al. Postpartum microalbuminuria after gestational diabetes: the impact of current glucose tolerance status. J Clin Endocrinol Metab. 2015; 100:1130–6.

21. De Souza LR, Berger H, Retnakaran R, Vlachou PA, Maguire JL, Nathens AB, et al. Non-alcoholic fatty liver disease in early pregnancy predicts dysglycemia in mid-pregnancy: prospective study. Am J Gastroenterol. 2016; 111:665–70.

22. Forbes S, Taylor-Robinson SD, Patel N, Allan P, Walker BR, Johnston DG. Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia. 2011; 54:641–7.

23. Ajmera VH, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, Terrault NA. Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease. Am J Gastroenterol. 2016; 111:658–64.

24. Foghsgaard S, Andreasen C, Vedtofte L, Andersen ES, Bahne E, Strandberg C, et al. Nonalcoholic fatty liver disease is prevalent in women with prior gestational diabetes mellitus and independently associated with insulin resistance and waist circumference. Diabetes Care. 2017; 40:109–16.

25. Mehmood S, Margolis M, Ye C, Maple-Brown L, Hanley AJ, Connelly PW, et al. Hepatic fat and glucose tolerance in women with recent gestational diabetes. BMJ Open Diabetes Res Care. 2018; 6:e000549.

26. Retnakaran R, Luo J, Shah BR. Gestational diabetes in young women predicts future risk of serious liver disease. Diabetologia. 2019; 62:306–10.

27. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019; 62:905–14.

28. Fadl H, Magnuson A, Ostlund I, Montgomery S, Hanson U, Schwarcz E. Gestational diabetes mellitus and later cardiovascular disease: a Swedish population based case-control study. BJOG. 2014; 121:1530–6.

29. Savitz DA, Danilack VA, Elston B, Lipkind HS. Pregnancy-induced hypertension and diabetes and the risk of cardiovascular disease, stroke, and diabetes hospitalization in the year following delivery. Am J Epidemiol. 2014; 180:41–4.

30. Tobias DK, Stuart JJ, Li S, Chavarro J, Rimm EB, Rich-Edwards J, et al. Association of history of gestational diabetes with longterm cardiovascular disease risk in a large prospective cohort of US women. JAMA Intern Med. 2017; 177:1735–42.

31. McKenzie-Sampson S, Paradis G, Healy-Profitos J, St-Pierre F, Auger N. Gestational diabetes and risk of cardiovascular disease up to 25 years after pregnancy: a retrospective cohort study. Acta Diabetol. 2018; 55:315–22.

32. Retnakaran R, Shah BR. Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study. Lancet Diabetes Endocrinol. 2019; 7:378–84.

33. Yu Y, Soohoo M, Sorensen HT, Li J, Arah OA. Gestational diabetes mellitus and the risks of overall and type-specific cardiovascular diseases: a population- and sibling-matched cohort study. Diabetes Care. 2022; 45:151–9.

34. Echouffo-Tcheugui JB, Guan J, Retnakaran R, Shah BR. Gestational diabetes and incident heart failure: a cohort study. Diabetes Care. 2021; 44:2346–52.

35. Verma A, Boney CM, Tucker R, Vohr BR. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Clin Endocrinol Metab. 2002; 87:3227–35.

36. Lauenborg J, Mathiesen E, Hansen T, Glumer C, Jorgensen T, Borch-Johnsen K, et al. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab. 2005; 90:4004–10.

37. Retnakaran R, Qi Y, Connelly PW, Sermer M, Zinman B, Hanley AJ. Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. J Clin Endocrinol Metab. 2010; 95:670–7.

38. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. J Clin Endocrinol Metab. 2010; 95:4345–53.

39. Tranidou A, Dagklis T, Tsakiridis I, Siargkas A, Apostolopoulou A, Mamopoulos A, et al. Risk of developing metabolic syndrome after gestational diabetes mellitus: a systematic review and meta-analysis. J Endocrinol Invest. 2021; 44:1139–49.

40. Tisi DK, Burns DH, Luskey GW, Koski KG. Fetal exposure to altered amniotic fluid glucose, insulin, and insulin-like growth factor-binding protein 1 occurs before screening for gestational diabetes mellitus. Diabetes Care. 2011; 34:139–44.

41. Sovio U, Murphy HR, Smith GC. Accelerated fetal growth prior to diagnosis of gestational diabetes mellitus: a prospective cohort study of nulliparous women. Diabetes Care. 2016; 39:982–7.

42. Retnakaran R. The insulin-like growth factor axis: a new player in gestational diabetes mellitus? Diabetes. 2016; 65:3246–8.

43. Gunderson EP, Quesenberry CP Jr, Jacobs DR Jr, Feng J, Lewis CE, Sidney S. Longitudinal study of prepregnancy cardiometabolic risk factors and subsequent risk of gestational diabetes mellitus: the CARDIA study. Am J Epidemiol. 2010; 172:1131–43.

44. Hedderson MM, Darbinian JA, Quesenberry CP, Ferrara A. Pregravid cardiometabolic risk profile and risk for gestational diabetes mellitus. Am J Obstet Gynecol. 2011; 205:55.

45. Harville EW, Viikari JS, Raitakari OT. Preconception cardiovascular risk factors and pregnancy outcome. Epidemiology. 2011; 22:724–30.

46. Retnakaran R, Shah BR. Divergent trajectories of cardiovascular risk factors in the years before pregnancy in women with and without gestational diabetes mellitus: a population-based study. Diabetes Care. 2020; 43:2500–8.

47. Retnakaran R, Shah BR. Impact of pregnancy on the trajectories of cardiovascular risk factors in women with and without gestational diabetes. Diabetes Obes Metab. 2021; 23:2364–73.

48. Retnakaran R. Diabetes in pregnancy 100 years after the discovery of insulin: hot topics and open questions to be addressed in the coming years. Metabolism. 2021; 119:154772.

49. Barker DJ. The fetal and infant origins of adult disease. BMJ. 1990; 301:1111.

50. Moore TR. A comparison of amniotic fluid fetal pulmonary phospholipids in normal and diabetic pregnancy. Am J Obstet Gynecol. 2002; 186:641–50.

51. Metzger BE, Persson B, Lowe LP, Dyer AR, Cruickshank JK, Deerochanawong C, et al. Hyperglycemia and adverse pregnancy outcome study: neonatal glycemia. Pediatrics. 2010; 126:e1545–52.

52. Dudley DJ. Diabetic-associated stillbirth: incidence, pathophysiology, and prevention. Clin Perinatol. 2007; 34:611–26.

53. Wu Y, Liu B, Sun Y, Du Y, Santillan MK, Santillan DA, et al. Association of maternal prepregnancy diabetes and gestational diabetes mellitus with congenital anomalies of the newborn. Diabetes Care. 2020; 43:2983–90.

54. Pedersen J. Diabetes mellitus and pregnancy: present status of the hyperglycaemia: hyperinsulinism theory and the weight of the newborn baby. Postgrad Med J. 1971; Suppl:66–7.

55. Catalano PM, Thomas A, Huston-Presley L, Amini SB. Increased fetal adiposity: a very sensitive marker of abnormal in utero development. Am J Obstet Gynecol. 2003; 189:1698–704.

56. Crume TL, Shapiro AL, Brinton JT, Glueck DH, Martinez M, Kohn M, et al. Maternal fuels and metabolic measures during pregnancy and neonatal body composition: the healthy start study. J Clin Endocrinol Metab. 2015; 100:1672–80.

57. Pirkola J, Pouta A, Bloigu A, Hartikainen AL, Laitinen J, Jarvelin MR, et al. Risks of overweight and abdominal obesity at age 16 years associated with prenatal exposures to maternal prepregnancy overweight and gestational diabetes mellitus. Diabetes Care. 2010; 33:1115–21.

58. Lowe WL Jr, Scholtens DM, Kuang A, Linder B, Lawrence JM, Lebenthal Y, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): maternal gestational diabetes mellitus and childhood glucose metabolism. Diabetes Care. 2019; 42:372–80.

59. Lowe WL Jr, Scholtens DM, Lowe LP, Kuang A, Nodzenski M, Talbot O, et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA. 2018; 320:1005–16.

60. Gillman MW, Rifas-Shiman S, Berkey CS, Field AE, Colditz GA. Maternal gestational diabetes, birth weight, and adolescent obesity. Pediatrics. 2003; 111:e221–6.

61. Pettitt DJ, Knowler WC, Bennett PH, Aleck KA, Baird HR. Obesity in offspring of diabetic Pima Indian women despite normal birth weight. Diabetes Care. 1987; 10:76–80.

62. Silverman BL, Rizzo T, Green OC, Cho NH, Winter RJ, Ogata ES, et al. Long-term prospective evaluation of offspring of diabetic mothers. Diabetes. 1991; 40 Suppl 2:121–5.

63. Gomes D, von Kries R, Delius M, Mansmann U, Nast M, Stubert M, et al. Late-pregnancy dysglycemia in obese pregnancies after negative testing for gestational diabetes and risk of future childhood overweight: an interim analysis from a longitudinal mother-child cohort study. PLoS Med. 2018; 15:e1002681.

64. Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes. 2000; 49:2208–11.

65. Josefson JL, Catalano PM, Lowe WL, Scholtens DM, Kuang A, Dyer AR, et al. The joint associations of maternal BMI and glycemia with childhood adiposity. J Clin Endocrinol Metab. 2020; 105:2177–88.

66. Hockett CW, Harrall KK, Moore BF, Starling AP, Bellatorre A, Sauder KA, et al. Persistent effects of in utero overnutrition on offspring adiposity: the Exploring Perinatal Outcomes among Children (EPOCH) study. Diabetologia. 2019; 62:2017–24.

67. Patro Golab B, Santos S, Voerman E, Lawlor DA, Jaddoe VW, Gaillard R, et al. Influence of maternal obesity on the association between common pregnancy complications and risk of childhood obesity: an individual participant data meta-analysis. Lancet Child Adolesc Health. 2018; 2:812–21.

68. Sauder KA, Hockett CW, Ringham BM, Glueck DH, Dabelea D. Fetal overnutrition and offspring insulin resistance and β-cell function: the Exploring Perinatal Outcomes among Children (EPOCH) study. Diabet Med. 2017; 34:1392–9.

69. Scholtens DM, Kuang A, Lowe LP, Hamilton J, Lawrence JM, Lebenthal Y, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): maternal glycemia and childhood glucose metabolism. Diabetes Care. 2019; 42:381–92.

70. Wicklow BA, Sellers EA, Sharma AK, Kroeker K, Nickel NC, Philips-Beck W, et al. Association of gestational diabetes and type 2 diabetes exposure in utero with the development of type 2 diabetes in first nations and non-first nations offspring. JAMA Pediatr. 2018; 172:724–31.

71. Pettitt DJ, Aleck KA, Baird HR, Carraher MJ, Bennett PH, Knowler WC. Congenital susceptibility to NIDDM: role of intrauterine environment. Diabetes. 1988; 37:622–8.

72. Dabelea D, Mayer-Davis EJ, Lamichhane AP, D'Agostino RB Jr, Liese AD, Vehik KS, et al. Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH Case-Control Study. Diabetes Care. 2008; 31:1422–6.

73. Poulsen P, Esteller M, Vaag A, Fraga MF. The epigenetic basis of twin discordance in age-related diseases. Pediatr Res. 2007; 61(5 Pt 2):38R–42R.

74. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008; 105:17046–9.

75. Ruchat SM, Houde AA, Voisin G, St-Pierre J, Perron P, Baillargeon JP, et al. Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. Epigenetics. 2013; 8:935–43.

76. Chen P, Piaggi P, Traurig M, Bogardus C, Knowler WC, Baier LJ, et al. Differential methylation of genes in individuals exposed to maternal diabetes in utero. Diabetologia. 2017; 60:645–55.

77. Fradin D, Boelle PY, Belot MP, Lachaux F, Tost J, Besse C, et al. Genome-wide methylation analysis identifies specific epigenetic marks in severely obese children. Sci Rep. 2017; 7:46311.

78. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes. 2011; 60:2624–34.

79. Bunt JC, Tataranni PA, Salbe AD. Intrauterine exposure to diabetes is a determinant of hemoglobin A(1)c and systolic blood pressure in pima Indian children. J Clin Endocrinol Metab. 2005; 90:3225–9.

80. Miranda JO, Cerqueira RJ, Barros H, Areias JC. Maternal diabetes mellitus as a risk factor for high blood pressure in late childhood. Hypertension. 2019; 73:e1–7.

81. Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care. 2014; 37:436–43.

82. Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care. 2012; 35:1265–71.

83. Sellers EA, Dart AB, McGavock J, Wicklow BA. Cardiovascular comorbidity associated with albuminuria in youth-onset type 2 diabetes: analyses from the iCARE study. Can J Diabetes. 2021; 45:458–65.

84. Sellers EA, Hadjiyannakis S, Amed S, Dart AB, Dyck RF, Hamilton J, et al. Persistent albuminuria in children with type 2 diabetes: a canadian paediatric surveillance program study. J Pediatr. 2016; 168:112–7.

85. Hoy WE, Ingelfinger JR, Hallan S, Hughson MD, Mott SA, Bertram JF. The early development of the kidney and implications for future health. J Dev Orig Health Dis. 2010; 1:216–33.

86. Hokke SN, Armitage JA, Puelles VG, Short KM, Jones L, Smyth IM, et al. Altered ureteric branching morphogenesis and nephron endowment in offspring of diabetic and insulin-treated pregnancy. PLoS One. 2013; 8:e58243.

87. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 1996; 49:1774–7.

88. West NA, Crume TL, Maligie MA, Dabelea D. Cardiovascular risk factors in children exposed to maternal diabetes in utero. Diabetologia. 2011; 54:504–7.

89. Perng W, Hockett CW, Sauder KA, Dabelea D. In utero exposure to gestational diabetes mellitus and cardiovascular risk factors in youth: a longitudinal analysis in the EPOCH cohort. Pediatr Obes. 2020; 15:e12611.

90. Grunnet LG, Hansen S, Hjort L, Madsen CM, Kampmann FB, Thuesen AC, et al. Adiposity, dysmetabolic traits, and earlier onset of female puberty in adolescent offspring of women with gestational diabetes mellitus: a clinical study within the Danish national birth cohort. Diabetes Care. 2017; 40:1746–55.

91. Guillemette L, Wicklow B, Sellers EA, Dart A, Shen GX, Dolinsky VW, et al. Intrauterine exposure to diabetes and risk of cardiovascular disease in adolescence and early adulthood: a population-based birth cohort study. CMAJ. 2020; 192:E1104–13.

92. Yu Y, Arah OA, Liew Z, Cnattingius S, Olsen J, Sorensen HT, et al. Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: population based cohort study with 40 years of follow-up. BMJ. 2019; 367:l6398.

93. Kereliuk SM, Dolinsky VW. Recent experimental studies of maternal obesity, diabetes during pregnancy and the developmental origins of cardiovascular disease. Int J Mol Sci. 2022; 23:4467.

94. Wicklow, B., & Retnakaran, R. (2023). Gestational diabetes mellitus and its implications across the life span. *Diabetes & Metabolism Journal*, *47*(3), 333-344.

سكري الحمل: إدارة المرض، السيطرة الصيدلانية، وخطط التدخل التمريضي

الملخص :

خلفية: سكري الحمل (GDM) هو حالة تتميز بعدم تحمل الجلوكوز الذي يتم اكتشافه أثناء الحمل، مما يشكل مخاطر كبيرة على صحة الأم والجنين. يزيد السكري الحمل من احتمالية حدوث نتائج ولادة سلبية مثل ضخامة الجنين، وتوقف الكتف، والولادة المبكرة، كما يزيد من الحاجة إلى إجراء عمليات قيصرية. علاوة على ذلك، فإن النساء اللاتي تم تشخيصهن بسكري الحمل معرضات بشكل أكبر لتطوير مرض السكري من النوع الثاني (T2DM) وأمراض القلب والأوعية الدموية (CVD) في وقت لاحق من حياتهن. تشير الدراسات الحديثة إلى أن تأثير سكري الحمل يمتد إلى ما بعد فترة الحمل، مما يؤثر بشكل محتمل على صحة الأم على المدى الطويل وصحة الأطفال.

الهدف: يهدف هذا المقال إلى استكشاف إدارة سكري الحمل، مع التركيز على دور الصيادلة والتدخلات التمريضية في السيطرة على المرض والتخفيف من تأثيراته الفورية وطويلة الأمد على صحة الأم والطفل.

الطرق: يستعرض المقال بيانات من دراسات مختلفة وملاحظات سريرية حول الفيزيولوجيا المرضية، إدارة المرض، والنتائج الطويلة الأمد المرتبطة بسكري الحمل. يتناول المقال صحة الأم بعد الحمل مع سكري الحمل، بما في ذلك زيادة خطر الإصابة بمرض السكري من النوع الثاني، وأمراض القلب والأوعية الدموية، والمضاعفات لدى الأطفال. كما يناقش دور التدخلات المبكرة، وعوامل الخطر، والتدابير الوقائية.

النتائج: يسلط المراجعة الضوء على العلاقة المهمة بين سكري الحمل وتطور مرض السكري من النوع الثاني وأمراض القلب والأوعية الدموية، مع التأكيد على تطور خلل وظيفة خلايا بيتا الذي يعد أساسًا لكل من الحالتين. بالإضافة إلى ذلك، يُظهر التقرير أن النساء اللواتي لديهن تاريخ من سكري الحمل يعانين من معدلات أعلى من السمنة وارتفاع ضغط الدم ومتلازمة الأيض بعد الولادة، مما يساهم في زيادة خطر المضاعفات الصحية المستقبلية. كما أن الأطفال المولودين لأمهات مصابات بسكري الحمل معرضون أيضًا لمشاكل طويلة الأمد في الصحة القلبية والتمثيل الغذائي.

الخلاصة: إن إدارة سكري الحمل أمر بالغ الأهمية ليس فقط لنتائج الحمل، ولكن أيضًا لصحة الأم والطفل على المدى الطويل. التدخل المبكر، بما في ذلك دور الصيادلة وموظفي التمريض في مراقبة التحكم في مستوى السكر في الدم وخطر الأمراض القلبية الوعائية، أمر بالغ الأهمية في تقليل مخاطر الإصابة بمرض السكري من النوع الثاني وأمراض القلب والأوعية الدموية. علاوة على ذلك، فإن التعرف على علامات الخلل الأيضي المبكرة في النساء قبل وأثناء الحمل يمكن أن يساعد في الوقاية من ظهور سكري الحمل والمضاعفات المرتبطة به.

الكلمات المفتاحية: سكري الحمل، مرض السكري من النوع الثاني، أمراض القلب والأوعية الدموية، خلل وظيفة خلايا بيتا، صحة الأم، التدخلات التمريضية، السيطرة الصيدلانية، متلازمة الأيض.